Tiny stem cell companies close in on major heart disease goals – Reuters
Reuters |
Tiny stem cell companies close in on major heart disease goals
Reuters Australia's Mesoblast, with a market value of about $500 million, is attempting to alter advanced heart failure, a leading cause of hospitalizations and deaths and an enormous cost burden. They are among the farthest along in the stem cell industry at … |
